Compare CWEN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWEN | LNTH |
|---|---|---|
| Founded | 2012 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.6B |
| IPO Year | 2013 | 2014 |
| Metric | CWEN | LNTH |
|---|---|---|
| Price | $30.70 | $100.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $42.00 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 1.1M | 962.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | ★ 11.94 | N/A |
| EPS | 0.75 | ★ 2.91 |
| Revenue | ★ $1,429,000,000.00 | $343,374,000.00 |
| Revenue This Year | $16.38 | N/A |
| Revenue Next Year | $8.48 | $14.19 |
| P/E Ratio | $41.28 | ★ $34.64 |
| Revenue Growth | ★ 4.23 | 3.62 |
| 52 Week Low | $27.90 | $49.67 |
| 52 Week High | $41.74 | $111.86 |
| Indicator | CWEN | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 48.37 |
| Support Level | N/A | $100.51 |
| Resistance Level | $33.87 | $101.43 |
| Average True Range (ATR) | 0.78 | 0.44 |
| MACD | -0.11 | 0.10 |
| Stochastic Oscillator | 17.95 | 49.80 |
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and the owner of modern, sustainable, and long-term contracted assets across North America. The company segments its operations into Flexible Generation, Renewables & Storage, and Corporate divisions. The majority of its revenue is generated from the Renewables & Storage segment.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.